3 completed, 3 unknown, 1 active not recruiting, 1 recruiting. 3 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Severe Acute Respiratory Infection: new trials by email Literature Review of Severe Acute Respiratory Infection trials Research Report on Severe Acute Respiratory Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV in Children Under 6 Months in Bogotá RSVpreF vaccine (Abrysvo) and Nirsevimab (Beyfortus) or unexposed - Respiratory Syncytial Virus Infections, Severe Acute Respiratory Infection | Active not recruiting | Bogotá District Health Secretariat | 1097 | 2026-01-01 | 2026-08-06 | |
| mNGS -Guided Antimicrobial Treatment in Early Severe Community-Acquired Pneumonia Among Immunocompromised Patients mNGS-guided treatment - Severe Acute Respiratory Infection, Community-acquired Pneumonia | Not applicable | Unknown | Qilu Hospital of Shandong University | 342 | 2022-08-19 | 2023-01-31 |
| NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone - Coronavirus Infection, Severe Acute Respiratory Infection | Phase 2 / Phase 3 | Unknown | Biomed Industries, Inc. | 525 | 2022-06-15 | 2022-02-16 |
| Viral Etiology of Severe Acute Respiratory InFection in CriticallY Ill Patients Registry Severe Acute Respiratory Infection | Terminated | King Abdullah International Medical Research Center | 13 | 2022-03-20 | 2024-10-04 | |
| The REDEEM Pilot Study: A Feasibility RCT of Early ECMO in Severe Acute Respiratory Infection, Including COVID-19, WHO VV-ECMO - Mechanical Ventilation Complication, Severe Acute Respiratory Infection | Not applicable | Completed | Australian and New Zealand Intensive Care Research Centre | 6 | 2021-03-01 | 2023-10-04 |
| Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg - Covid19, Corona Virus Infection | Phase 1 | Unknown | Biomed Industries, Inc. | 45 | 2020-09-15 | 2020-07-21 |
| Short Period Incidence Study of Severe Acute Respiratory Illness Severe Acute Respiratory Infection | Recruiting | Australian and New Zealand Intensive Care Research Centre | 15000 | 2016-01-01 | 2024-08-09 | |
| Clinical Trial to Assess the Influenza Vaccination of the Hospitalized Adults nasopharyngeal sample - Severe Acute Respiratory Infection | Not applicable | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 6173 | 2014-01-01 | 2026-04-24 |
| Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020) respiratory specimen - Influenza Viral Infections, Respiratory Viral Infection | Completed | Sciensano | 12145 | 2012-01-20 | 2023-09-08 |
COVID-19 (3) · Coronavirus Infections (2) · Infections (2) · Pneumonia (2) · Severe Acute Respiratory Syndrome (2) · Bronchiolitis, Viral (1) · Cognitive Dysfunction (1) · Community-Acquired Pneumonia (1) · Critical Illness (1) · Influenza, Human (1) · Nerve Degeneration (1) · Neuroinflammatory Diseases (1) · Respiratory Syncytial Virus Infections (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Respiratory Tract Diseases (6) · Infections (5) · Lung Diseases (5) · RNA Virus Infections (5) · Respiratory Tract Infections (5) · Virus Diseases (5) · Coronaviridae Infections (3) · Nidovirales Infections (3) · Pneumonia, Viral (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Pneumonia (2) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchitis (1)
Atazanavir Sulfate (1) · Dexamethasone (1) · Respiratory Rate (1) · abrysvo (1) · nirsevimab (1) · remdesivir (1)
Australian and New Zealand Intensive Care Research Centre (2) · Biomed Industries, Inc. (2) · Bogotá District Health Secretariat (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · King Abdullah International Medical Research Center (1) · Qilu Hospital of Shandong University (1) · Sciensano (1)
Australia (2) · United States (2) · China (1) · Colombia (1) · France (1) · Germany (1) · Saudi Arabia (1)
Lloyd Tran, PhD (2) · Aidan Burrell, MBBS (1) · Odile Launay, PU-PH (1) · Yaseen Arabi (1)
PMID 27105315, PMID 27903461, PMID 31589554, PMID 32056143, PMID 32283266, PMID 33006303, PMID 33937883, PMID 34446468, PMID 34558405, PMID 35273311, PMID 35983331, PMID 37470740